NCT06419660已完成1 期
The Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of a Single Oral Dose BI 3000202 in Healthy Male Subjects (an Open-label, Randomized, Two-way Cross-over Study)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Maximum measured concentration of the analyte in plasma (Cmax)
研究概览
简要总结
The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 3000202 in plasma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests
- •Age of 18 to 55 years (inclusive)
- •Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
- •Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
研究组 & 干预措施
Esomeprazole + BI 300202 (T) then BI 300202 (R) treatment
Experimental
T=test R=reference
干预措施: BI 300202 (Drug)
Esomeprazole + BI 300202 (T) then BI 300202 (R) treatment
Experimental
T=test R=reference
干预措施: esomeprazole (Drug)
BI 300202 (R) then esomeprazole + BI 300202 (T) treatment
Experimental
干预措施: BI 300202 (Drug)
BI 300202 (R) then esomeprazole + BI 300202 (T) treatment
Experimental
干预措施: esomeprazole (Drug)
结局指标
主要结局
Maximum measured concentration of the analyte in plasma (Cmax)
时间窗: Up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
时间窗: Up to 4 days
次要结局
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)(Up to 4 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the BloodHealthyNCT05467475Boehringer Ingelheim15
已完成
1 期
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult ParticipantsHealthy VolunteersNCT03849690Millennium Pharmaceuticals, Inc.12
Unknown
4 期
Study of Long-Term Use of Proton-Pump-Inhibitors in General PracticeGastroesophageal RefluxdiseaseUlcerDyspepsiaNCT00363701Glostrup University Hospital, Copenhagen150
已完成
1 期
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of IsavuconazolePharmacokinetics of IsavuconazoleHealthy SubjectsNCT02128893Astellas Pharma Global Development, Inc.24
已完成
3 期
Reflux Esophagitis Phase III Study (Maintenance Treatment)Reflux EsophagitisNCT00634114AstraZeneca540